STOCK TITAN

Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Castle Biosciences, Inc. (NASDAQ: CSTL) will release its financial results for the first quarter ended March 31, 2023, on May 3, 2023, after market close. Management will conduct a conference call and webcast at 4:30 p.m. Eastern Time to discuss these results. Interested parties can access the live webcast through the Company's Investor Relations page, with a replay available afterward. Castle Biosciences provides innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions, and is progressing with R&D for other high-need diseases, including therapies for psoriasis and atopic dermatitis.

Positive
  • Upcoming financial results presentation may lead to positive market response.
  • The company is actively developing tests for diseases with high clinical needs.
Negative
  • None.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2023, after the close of market on Wednesday, May 3, 2023.

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Conference Call and Webcast Details

A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/614563599, or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.

To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 083848. International dial-in numbers are available here: https://www.netroadshow.com/events/global-numbers?confId=48738; please use the same access code above to join the call.

There will be a brief Question and Answer session following management commentary.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

When will Castle Biosciences release its Q1 2023 financial results?

Castle Biosciences will release its Q1 2023 financial results on May 3, 2023.

What time is the conference call for Castle Biosciences' financial results?

The conference call for Castle Biosciences' financial results is scheduled for 4:30 p.m. Eastern Time on May 3, 2023.

Where can I access the Castle Biosciences webcast for their financial results?

The webcast can be accessed through the Investor Relations page on Castle Biosciences' website.

What does Castle Biosciences specialize in?

Castle Biosciences specializes in innovative diagnostic tests for various conditions, including skin cancers and mental health.

Castle Biosciences, Inc.

NASDAQ:CSTL

CSTL Rankings

CSTL Latest News

CSTL Stock Data

842.46M
27.11M
3.25%
95.3%
5.74%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FRIENDSWOOD